Download PDF
CC BY-NC-ND 4.0 · Endosc Int Open 2017; 05(06): E430-E449
DOI: 10.1055/s-0043-106578
Original article
Eigentümer und Copyright ©Georg Thieme Verlag KG 2017

Recurrence of intestinal metaplasia and early neoplasia after endoscopic eradication therapy for Barrett’s esophagus: a systematic review and meta-analysis[*]

Larissa L. Fujii-Lau   **
1   Washington University School of Medicine, St. Louis, MO, USA
,
Birtukan Cinnor   **
2   University of Colorado Anschutz Medical Campus, Aurora, CO, USA
,
Nicholas Shaheen
3   University of North Carolina, Chapel Hill, NC, USA
,
Srinivas Gaddam
1   Washington University School of Medicine, St. Louis, MO, USA
,
Srinadh Komanduri
4   Feinberg School of Medicine Northwestern University, Chicago, IL, USA
,
V. Raman Muthusamy
5   University of California, Los Angeles, Los Angeles, CA, USA
,
Ananya Das
6   Arizona Center for Digestive Health, Gilbert, AZ, USA
,
Robert Wilson
2   University of Colorado Anschutz Medical Campus, Aurora, CO, USA
,
Violette C. Simon
2   University of Colorado Anschutz Medical Campus, Aurora, CO, USA
,
Vladimir Kushnir
1   Washington University School of Medicine, St. Louis, MO, USA
,
Daniel Mullady
1   Washington University School of Medicine, St. Louis, MO, USA
,
Steven A. Edmundowicz
2   University of Colorado Anschutz Medical Campus, Aurora, CO, USA
,
Dayna S. Early
1   Washington University School of Medicine, St. Louis, MO, USA
,
Sachin Wani
2   University of Colorado Anschutz Medical Campus, Aurora, CO, USA
› Author Affiliations
Further Information

Publication History

submitted 22 November 2016

accepted after revision 15 February 2017

Publication Date:
31 May 2017 (online)

Also available at
   Permissions and Reprints

Abstract

Background Conflicting data exist with regard to recurrence rates of intestinal metaplasia (IM) and dysplasia after achieving complete eradication of intestinal metaplasia (CE-IM) in Barrett’s esophagus (BE) patients.

Aim (i) To determine the incidence of recurrent IM and dysplasia achieving CE-IM and (ii) to compare recurrence rates between treatment modalities [radiofrequency ablation (RFA) with or without endoscopic mucosal resection (EMR) vs stepwise complete EMR (SRER)].

Methods A systematic search was performed for studies reporting on outcomes and estimates of recurrence rates after achieving CE-IM. Pooled incidence [per 100-patient-years (PY)] and risk ratios with 95 %CI were obtained. Heterogeneity was measured using the I 2 statistic. Subgroup analyses, decided a priori, were performed to explore heterogeneity in results.

Results A total of 39 studies were identified (25-RFA, 13-SRER, and 2 combined). The pooled incidence of any recurrence was 7.5 (95 %CI 6.1 – 9.0)/100 PY with a pooled incidence of IM recurrence rate of 4.8 (95 %CI 3.8 – 5.9)/100 PY, and dysplasia recurrence rate of 2.0 (95 %CI 1.5 – 2.5)/100 PY. Compared to the SRER group, the RFA group had significantly higher overall [8.6 (6.7 – 10.5)/100 PY vs. 5.1 (3.1 – 7)/100 PY, P = 0.01] and IM recurrence rates [5.8 (4.3 – 7.3)/100 PY vs. 3.1 (1.7 – 4)/100 PY, P < 0.01] with no difference in recurrence rates of dysplasia. Significant heterogeneity between studies was identified. The majority of recurrences were amenable to repeat endoscopic eradication therapy (EET).

Conclusion The results of this study demonstrate that the incidence rates of overall, IM, and dysplasia recurrence rates post-EET are not inconsiderable and reinforce the importance of close surveillance after achieving CE-IM.

* Results of this study were presented in part at Digestive Disease Week 2015, Washington, DC, USA


** Drs Fujii-Lau and Cinnor contributed equally to this manuscript and are joint first authors.


 

  • References

  • 1 Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97: 142-146
    CrossrefPubMedGoogle Scholar
  • 2 Lepage C, Rachet B, Jooste V. et al. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol 2008; 103: 2694-2699
    CrossrefPubMedGoogle Scholar
  • 3 Crane SJ, Locke 3rd GR, Harmsen WS. et al. Survival trends in patients with gastric and esophageal adenocarcinomas: a population-based study. Mayo Clin Proc 2008; 83: 1087-1094
    CrossrefPubMedGoogle Scholar
  • 4 Polednak AP. Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas. Int J Cancer 2003; 105: 98-100
    CrossrefPubMedGoogle Scholar
  • 5 Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett’s oesophagus. Gut 1991; 32: 1441-1446
    CrossrefPubMedGoogle Scholar
  • 6 Devesa SS, Blot WJ, Fraumeni JF. et al. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-2053
    CrossrefPubMedGoogle Scholar
  • 7 Hur C, Miller M, Kong CY. et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 2013; 119: 1149-1158
    CrossrefPubMedGoogle Scholar
  • 8 Shaheen NJ, Falk GW, Iyer PG. et al. ACG clinical guideline: Diagnosis and management of Barrett’s esophagus. Am J Gastroenterol 2016; 111: 30-50 , quiz 51
    CrossrefPubMedGoogle Scholar
  • 9 Ronkainen J, Aro P, Storskrubb T. et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology 2005; 129: 1825-1831
    CrossrefPubMedGoogle Scholar
  • 10 Zagari RM, Fuccio L, Wallander MA. et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008; 57: 1354-1359
    CrossrefPubMedGoogle Scholar
  • 11 Wani S, Falk GW, Post J. et al. Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology 2011; 141: 1179-1186 , 1186 e1
    CrossrefPubMedGoogle Scholar
  • 12 Rastogi A, Puli S, El-Serag HB. et al. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc 2008; 67: 394-398
    CrossrefPubMedGoogle Scholar
  • 13 Wani S, Falk G, Hall M. et al. Patients with nondysplastic Barrett’s esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011; 9: 220-227 , quiz e26
    CrossrefPubMedGoogle Scholar
  • 14 Hvid-Jensen F, Pedersen L, Drewes AM. et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. NEJM 2011; 365: 1375-1383
    CrossrefPubMedGoogle Scholar
  • 15 Bhat S, Coleman HG, Yousef F. et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011; 103: 1049-1057
    CrossrefPubMedGoogle Scholar
  • 16 Wani S, Sharma P. Challenges with endoscopic therapy for Barrett’s esophagus. Gastroenterol Clin North Am 2015; 44: 355-372
    CrossrefPubMedGoogle Scholar
  • 17 Konda VJ, Waxman I. Endotherapy for Barrett’s esophagus. Am J Gastroenterol 2012; 107: 827-833
    CrossrefPubMedGoogle Scholar
  • 18 Wani S, Early D, Edmundowicz S. et al. Management of high-grade dysplasia and intramucosal adenocarcinoma in Barrett’s esophagus. Clin Gastroenterol Hepatol 2012; 10: 704-711
    CrossrefPubMedGoogle Scholar
  • 19 Wani S, Drahos J, Cook MB. et al. Comparison of endoscopic therapies and surgical resection in patients with early esophageal cancer: a population-based study. Gastrointest Endosc 2014; 79: 224-232e1
    CrossrefPubMedGoogle Scholar
  • 20 Shaheen NJ, Sharma P, Overholt BF. et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. NEJM 2009; 360: 2277-2288
    CrossrefPubMedGoogle Scholar
  • 21 Phoa KN, van Vilsteren FG, Weusten BL. et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA 2014; 311: 1209-1217
    CrossrefPubMedGoogle Scholar
  • 22 Wolf WA, Pasricha S, Cotton C. et al. Incidence of esophageal adenocarcinoma and causes of mortality after radiofrequency ablation of Barrett’s esophagus. Gastroenterology 2015; 149: 1752-1761.e1
    CrossrefPubMedGoogle Scholar
  • 23 Pech O, Behrens A, May A. et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut 2008; 57: 1200-1206
    CrossrefPubMedGoogle Scholar
  • 24 Wani S, Komanduri S, Muthusamy VR. Endoscopic eradication therapy in Barrett’s esophagus-related neoplasia: setting the bar right to optimize patient outcomes. Gastroenterology 2016; 150: 772-774
    CrossrefPubMedGoogle Scholar
  • 25 Gerke H, Siddiqui J, Nasr I. et al. Efficacy and safety of EMR to completely remove Barrett’s esophagus: experience in 41 patients. Gastrointest Endosc 2011; 74: 761-771
    CrossrefPubMedGoogle Scholar
  • 26 Chung A, Bourke MJ, Hourigan LF. et al. Complete Barrett’s excision by stepwise endoscopic resection in short-segment disease: long-term outcomes and predictors of stricture. Endoscopy 2011; 43: 1025-1032
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Anders M, Bahr C, El-Masry MA. et al. Long-term recurrence of neoplasia and Barrett’s epithelium after complete endoscopic resection. Gut 2014; 63: 1535-1543
    CrossrefPubMedGoogle Scholar
  • 28 Konda VJ, Gonzalez Haba Ruiz M, Koons A. et al. Complete endoscopic mucosal resection is effective and durable treatment for Barrett’s-associated neoplasia. Clin Gastroenterol Hepatol 2014; 12: 2002-2010 , e1–2
    CrossrefPubMedGoogle Scholar
  • 29 Pouw RE, Seewald S, Gondrie JJ. et al. Stepwise radical endoscopic resection for eradication of Barrett’s oesophagus with early neoplasia in a cohort of 169 patients. Gut 2010; 59: 1169-1177
    CrossrefPubMedGoogle Scholar
  • 30 Shaheen NJ, Overholt BF, Sampliner RE. et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology 2011; 141: 460-468
    CrossrefPubMedGoogle Scholar
  • 31 Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett’s esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1245-1255
    CrossrefPubMedGoogle Scholar
  • 32 Pasricha S, Bulsiewicz WJ, Hathorn KE. et al. Durability and predictors of successful radiofrequency ablation for Barrett’s esophagus. Clin Gastroenterol Hepatol 2014; 12: 1840-1847e1
    CrossrefPubMedGoogle Scholar
  • 33 Phoa KN, Pouw RE, van Vilsteren FG. et al. Remission of Barrett’s esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology 2013; 145: 96-104
    CrossrefPubMedGoogle Scholar
  • 34 van Vilsteren FG, Pouw RE, Seewald S. et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett’s oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. Gut 2011; 60: 765-773
    CrossrefPubMedGoogle Scholar
  • 35 Gupta M, Iyer PG, Lutzke L. et al. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett’s esophagus: results from a US Multicenter Consortium. Gastroenterology 2013; 145: 79-86e1
    CrossrefPubMedGoogle Scholar
  • 36 Vaccaro BJ, Gonzalez S, Poneros JM. et al. Detection of intestinal metaplasia after successful eradication of Barrett’s esophagus with radiofrequency ablation. Dig Dis Sci 2011; 56: 1996-2000
    CrossrefPubMedGoogle Scholar
  • 37 Moher D, Liberati A, Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-269 , W64
    CrossrefPubMedGoogle Scholar
  • 38 Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998; 52: 377-384
    CrossrefPubMedGoogle Scholar
  • 39 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188
    CrossrefPubMedGoogle Scholar
  • 40 Agoston AT, Strauss AC, Dulai PS. et al. Predictors of treatment failure after radiofrequency ablation for intramucosal adenocarcinoma in Barrett esophagus: A multi-institutional retrospective cohort study. Am J Surg Pathol 2016; 40: 554-562
    CrossrefPubMedGoogle Scholar
  • 41 Le Page PA, Velu PP, Penman ID. et al. Surgical and endoscopic management of high grade dysplasia and early oesophageal adenocarcinoma. Surgeon 2016; 14: 315-321
    CrossrefPubMedGoogle Scholar
  • 42 Orman ES, Kim HP, Bulsiewicz WJ. et al. Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett’s esophagus with radiofrequency ablation. Am J Gastroenterol 2013; 108: 187-195 , quiz 196
    CrossrefPubMedGoogle Scholar
  • 43 Cotton CC, Wolf WA, Pasricha S. et al. Recurrent intestinal metaplasia after radiofrequency ablation for Barrett’s esophagus: endoscopic findings and anatomic location. Gastrointest Endosc 2015; 81: 1362-1369
    CrossrefPubMedGoogle Scholar
  • 44 Small AJ, Sutherland SE, Hightower JS. et al. Comparative risk of recurrence of dysplasia and carcinoma after endoluminal eradication therapy of high-grade dysplasia versus intramucosal carcinoma in Barrett’s esophagus. Gastrointest Endosc 2015; 81: 1158-1166 , e1–4
    CrossrefPubMedGoogle Scholar
  • 45 Akiyama J, Roorda AK, Marcus SN. et al. Erosive esophagitis is a major predictor for recurrence of Barrett’s esophagus after successful radiofrequency ablation. Gastroenterology 2013; 144: S692
    PubMedGoogle Scholar
  • 46 Lada MJ, Watson TJ, Shakoor A. et al. Eliminating a need for esophagectomy: endoscopic treatment of Barrett esophagus with early esophageal neoplasia. Semin Thorac Cardiovasc Surg 2014; 26: 274-284
    CrossrefPubMedGoogle Scholar
  • 47 Shue P, Kataria R, Pathikonda R. et al. Factors associated with recurrence of Barrett’s esophagus after completion of radiofrequency ablation. Gastroenterology 2013; 144: S697
    PubMedGoogle Scholar
  • 48 Fitzgerald RC, di Pietro M, Ragunath K. et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut 2014; 63: 7-42
    CrossrefPubMedGoogle Scholar
  • 49 Spechler SJ, Sharma P, Souza RF. et al. American Gastroenterological Association technical review on the management of Barrett’s esophagus. Gastroenterology 2011; 140: e18-52 , quiz e13
    PubMedGoogle Scholar
  • 50 Krishnamoorthi R, Singh S, Ragunathan K. et al. Risk of recurrence of Barrett’s esophagus after successful endoscopic therapy. Gastrointest Endosc 2016; 83: 1090-1106e3
    CrossrefPubMedGoogle Scholar
  • 51 Wani S, Komanduri S, Early DS. et al. Determining effectiveness and recurrence post endoscopic eradication therapy (EET) in Barrett’s esophagus: results from a multicenter cohort study. Gastroenterology 2016; 150: S178
    PubMedGoogle Scholar
  • 52 Fleischer DE, Overholt BF, Sharma VK. et al. Endoscopic radiofrequency ablation for Barrett’s esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy 2010; 42: 781-789
    Article in Thieme ConnectPubMedGoogle Scholar
  • 53 Alvarez Herrero L, van Vilsteren FGI, Pouw RE. et al. Endoscopic radiofrequency ablation combined with endoscopic resection for early neoplasia in Barrett’s esophagus longer than 10 cm. Gastrointest Endosc 2011; 73: 682-690
    CrossrefPubMedGoogle Scholar
  • 54 Caillol F, Bories E, Pesenti C. et al. Radiofrequency ablation associated to mucosal resection in the oesophagus: experience in a single centre. Clin Res Hepatol Gastroenterol 2012; 36: 371-377
    CrossrefPubMedGoogle Scholar
  • 55 Gupta N, Wani S, Hollander TG. et al. Recurrence of disease after endoscopic eradication therapy (Eet) for Barrett’s esophagus (BE) with high grade dysplasia (HGD) and early cancer (EC). Gastroenterology 2012; 142: S750-S751
    PubMedGoogle Scholar
  • 56 van Vilsteren FG, Alvarez Herrero L, Pow RE. et al. Radiofrequency ablation and endoscopic resection in a single session for Barrett’s esophagus containing early neoplasia: a feasibility study. Endoscopy 2012; 44: 1096-1104
    Article in Thieme ConnectPubMedGoogle Scholar
  • 57 Dulai PS, Pohl H, Levenick JM. et al. Radiofrequency ablation for long- and ultralong-segment Barrett’s esophagus: a comparative long-term follow-up study. Gastrointest Endosc 2013; 77: 534-541
    CrossrefPubMedGoogle Scholar
  • 58 Ertan A, Zaheer I, Correa AM. et al. Photodynamic therapy vs radiofrequency ablation for Barrett’s dysplasia: Efficacy, safety and cost-comparison. World J Gastroenterol 2013; 19: 7106-7113
    CrossrefPubMedGoogle Scholar
  • 59 Haidry RJ, Dunn JM, Butt MA. et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett’s esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology 2013; 145: 87-95
    CrossrefPubMedGoogle Scholar
  • 60 Korst JR, Santana-Joseph S, Rutledge JR. et al. Patterns of recurrent and persistent intestinal metaplasia after successful radiofrequency ablation of Barrett’s esophagus. J Thorac Cardiovasc Surg 2013; 145: 1529-1534
    CrossrefPubMedGoogle Scholar
  • 61 Strauss AC, Agoston T, Dulai PS. et al. Radiofrequency ablation for Barrett’s-associated intramucosal carcinoma: a multi-center follow-up study. Surg Endosc 2014; 28: 3366-3372
    CrossrefPubMedGoogle Scholar
  • 62 Lada MJ, Watson TJ, Shakoor A. et al. Eliminating a need for esophagectomy: endoscopic treatment of Barrett esophagus with early esophageal neoplasia. Semin Thorac Cardiovasc Surg 2014; 26: 274-284
    CrossrefPubMedGoogle Scholar
  • 63 Le Page PA, Velu PP, Penman ID. et al. Surgical and endoscopic management of high grade dysplasia and early oesophageal adenocarcinoma. Surgeon 2016; 14: 315-321
    CrossrefPubMedGoogle Scholar
  • 64 Phoa KN, Pouw RE, Bisschops R. et al. Multimodality endoscopic eradication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II). Gut 2015; 65: 555-562
    PubMedGoogle Scholar
  • 65 Giovannini M, Bories E, Pesenti C. et al. Circumferential endoscopic mucosal resection in Barrett’s esophagus with high-grade intraepithelial neoplasia or mucosal cancer. Preliminary results in 21 patients. Endoscopy 2004; 36: 782-787
    Article in Thieme ConnectPubMedGoogle Scholar
  • 66 Larghi A, Lightdale CJ, Ross AS. et al. Long-term follow-up of complete Barrett’s eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma. Endoscopy 2007; 39: 1086-1091
    Article in Thieme ConnectPubMedGoogle Scholar
  • 67 Lopes CV, Hela M, Pesenti C. et al. Circumferential endoscopic resection of Barrett’s esophagus with high-grade dysplasia or early adenocarcinoma. Surg Endosc 2007; 21: 820-824
    CrossrefPubMedGoogle Scholar
  • 68 Chennat J, Konda VJA, Ross AS. et al. Complete Barrett’s eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma – an American single-center experience. Am J Gastroenterol 2009; 104: 2684-2692
    CrossrefPubMedGoogle Scholar
  • 69 Brahmania M, Lam E, Telford J. et al. Endoscopic mucosal resection: early experience in British Columbia. Can J Gastroenterol 2010; 24: 239-244
    CrossrefPubMedGoogle Scholar
  • 70 Moss A, Bourk MJ, Hourigan LF. et al. Endoscopic resection for Barrett’s high-grade dysplasia and early esophageal adenocarcinoma: an essential staging procedure with long-term therapeutic benefit. Am J Gastroenterol 2010; 105: 1276-1283
    CrossrefPubMedGoogle Scholar
  • 71 Conio M, Fisher D, Blanchi S. et al. One-step circumferential endoscopic mucosal cap resection of Barrett’s esophagus with early neoplasia. Clin Res Hepatol Gastroenterol 2014; 38: 81-91
    CrossrefPubMedGoogle Scholar
  • 72 Belghazi K, van Vilsteren FG, Weusten BL. et al. Long-term follow-up results of stepwise radical endoscopic resection for Barrett’s esophagus with early neoplasia. Gastrointest Endosc 2016; 83: AB555
    PubMedGoogle Scholar
  • 73 Waxman I, Vennelaganti S, Vennalaganti P. et al. Recurrence rates after multi-modality endoscopic eradication therapy for dysplastic Barrett’s esophagus (BE) and early esophageal cancer: results from an international, multi-center consortium. Gastrointest Endosc 2016; 83: AB121-AB122
    PubMedGoogle Scholar